-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Iovance Biotherapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- Iovance Biotherapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$89.1M, a 24.8% increase year-over-year.
- Iovance Biotherapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$430M, a 3.67% increase year-over-year.
- Iovance Biotherapeutics, Inc. annual Operating Income (Loss) for 2023 was -$461M, a 15.5% decline from 2022.
- Iovance Biotherapeutics, Inc. annual Operating Income (Loss) for 2022 was -$399M, a 16.4% decline from 2021.
- Iovance Biotherapeutics, Inc. annual Operating Income (Loss) for 2021 was -$343M, a 30.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)